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Background
Lactobacillus spp. are commensal bacteria that have long
been utilized as probiotics and are generally regarded as
safe for use in humans. We are currently investigating the
use of Lactobacillus spp. as vaccine vectors for oral immu-
nization against HIV infection. While some lactobacilli
seem to induce oral tolerance, others induce an adaptive
immune response. The differences in these responses may
be due to activation of specific Toll-like receptors (TLR).
Methods
Using HEK293 cells engineered to express single TLRs, we
determined the ability of mutant and wild-type L. gasseri
and L. acidophilus to activate TLR1/2, TLR2/6, TLR2
(homodimer), TLR3, TLR4/MD2, TLR5, TLR7, TLR8 and
TLR9.
Results
Our data show that Lactobacillus species primarily acti-
vate TLR 2/6, with additional, though lesser, activation of
TLR1/2 and TLR2. Bacteria with mutations in mucus bind-
ing proteins tended to induce greater activation through
TLR2/6 compared to wild-type bacteria. The TLR activa-
tion profile of L. gasseri genetically engineered to express
feline immunodeficiency virus (FIV) gag protein did not
differ from wild-type bacteria, however, L. gasseri express-
ing human immunodeficiency virus (HIV) gag protein
showed a modest increase in TLR 2/6 activation. In order
to expand the TLR activation profile, we transfected L. gas-
seri with a plasmid expressing FliC, the gene encoding bac-
terial Flagellin which activates TLR5. Indeed, this
recombinant L. gasseri demonstrated strong activation of
TLR5 and TLR2/6 as well as moderate activation through
TLR1/2 and TLR2.
Conclusion
In conclusion, Lactobacillus species can be modified either
by mutation of genes or addition of genes to modulate its
TLR activation profile to enhance immunogenicity as a
vaccine vector.
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